hydrochlorothiazide (HCTZ, HydroDIURIL, Oretic, Esidrix)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradenames: HCTZ, HydroDiuril, Oretic.

Indications

Dosage

  • hypertension:
    • 12.5-50 mg/day
    • elderly: 12.5 mg QD
    • maintenance doses > 50 mg/day provide little additional benefit in controlling hypertension
    • dose should rarely exceed 25 mg QD[6]
    • no proof that low-dose HCTZ improves outcomes; at least 50 mg of HCTZ QD used in trials that found improved outcomes[10]
  • edema: 25-200 mg/day QD or divided BID/TID

Tabs: 25, 50, 100 mg

Solution: 50 mg/5 mL

Pharmacokinetics

elimination via liver

protein binding = 58 %

Adverse effects

Drug interactions

Mechanism of action

More general terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996.
  2. Manual of Medical Therapeutics, 28th ed, Ewald & McKenzie (eds), Little, Brown & Co, Boston, 1995, pg 123
  3. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  4. Jump up to: 4.0 4.1 Medical Knowledge Self Assessment Program (MKSAP) 11, 18. American College of Physicians, Philadelphia 1998, 2018
  5. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  6. Jump up to: 6.0 6.1 Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
  7. Jump up to: 7.0 7.1 Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 470
  8. Jump up to: 8.0 8.1 LaCroix AZ et al, Low-dose hydrochlorthiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo- controlled trial. Ann Intern Med 133:516, 2000 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11015164
  9. Jump up to: 9.0 9.1 MicroMedex
  10. Jump up to: 10.0 10.1 Prescriber's Letter 18(3): 2011 COMMENTARY: Thiazides for Hypertension CHART: Comparison of Commonly Used Diuretics Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=270304&pb=PRL (subscription needed) http://www.prescribersletter.com
  11. Friedman GD et al Antihypertensive Drugs and Lip Cancer in Non-Hispanic Whites Archives of Internal Medicine, August 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22869299 <Internet> http://archinte.jamanetwork.com/article.aspx?articleid=1307567
  12. Jump up to: 12.0 12.1 Weber MA et al. Effects of body size and hypertension treatments on cardiovascular event rates: Subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 2013 Feb 16; 381:537 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23219284
    Messerli FH and Bangalore S. Diuretic-based regimens for obese patients? Lancet 2013 Feb 16; 381:512. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23219285
  13. Jump up to: 13.0 13.1 13.2 Pottegard A, Pedersen SA, Schmidt SAJ et al Association of Hydrochlorothiazide Use and Risk of Malignant Melanoma. JAMA Intern Med. Published online May 29, 2018. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29813157 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2682616
    Pedersen SA, Gaist D, Schmidt SAJ et al Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol. 2018 Apr;78(4):673-681.e9. Epub 2017 Dec 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29217346 Free Article
  14. Jump up to: 14.0 14.1 14.2 14.3 Hripcsak G, Suchard MA, Shea S et al Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. JAMA Intern Med. Published online February 17, 2020. PMID: https://www.ncbi.nlm.nih.gov/pubmed/32065600 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2760777
  15. Jump up to: 15.0 15.1 15.2 FDA. Aug 20, 2020 FDA approves label changes to hydrochlorothiazide to describe small risk of non-melanoma skin cancer. https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-label-changes-hydrochlorothiazide-describe-small-risk-non-melanoma-skin-cancer
  16. Jump up to: 16.0 16.1 Schneider R, Reinau D, Stoffel S et al Risk of skin cancer in new users of thiazides and thiazide-like diuretics: a cohort study using an active comparator group. Br J Dermatol. Published online February 20, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/33609289
  17. Jump up to: 17.0 17.1 Geriatric Review Syllabus, 11th edition (GRS11) Harper GM, Lyons WL, Potter JF (eds) American Geriatrics Society, 2022
  18. Jump up to: 18.0 18.1 Ishani A, Cushman WC, Leatherman SM et al Chlorthalidone vs. Hydrochlorothiazide for Hypertension - Cardiovascular Events. N Engl J Med 2022. Dec 14 PMID: https://www.ncbi.nlm.nih.gov/pubmed/26760416 https://www.nejm.org/doi/10.1056/NEJMoa2212270
  19. Jump up to: 19.0 19.1 Andersson NW, Wohlfahrt J, Feenstra B, Hviid A, Melbye M, Lund M. Cumulative Incidence of Thiazide-Induced Hyponatremia. A Population-Based Cohort Study. Ann Inter Med 2023. Dec 19. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38109740 https://www.acpjournals.org/doi/full/10.7326/M23-1989
  20. Jump up to: 20.0 20.1 NEJM Knowledge+
  21. Jump up to: 21.0 21.1 Ishani A, Hau C, Raju S et al Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 Dec 2;7(12):e2449576. PMID: https://www.ncbi.nlm.nih.gov/pubmed/39656458 Free PMC article. Clinical Trial.

Database